HDAC6 and Parkinson disease: Considering the anti-inflammatory properties of HDAC6-specific inhibitors, this study investigated the effects of pharmacological inhibition of HDAC6 by tubastatin A (TBA), an HDAC6 selective inhibitor, on activation of NLRP3 inflammatory response and characterized the effects of TBA on PD pathogenesis in in vitro and in vivo PD models.